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Abstract: Liver fibrosis can progress to cirrhosis, which is considered a serious disease.
The Child-Pugh score and the model of end-stage liver disease score have been established to
assess residual liver function in patients with liver cirrhosis. The development of portal hypertension
contributes to ascites, variceal bleeding and further complications in these patients. A transjugular
intrahepatic portosystemic shunt (TIPS) is used to lower portal pressure, which represents a major
improvement in the treatment of patients. Adipokines are proteins released from adipose tissue and
modulate hepatic fibrogenesis. These proteins affect various biological processes that are involved in
liver function, including angiogenesis, vasodilation, inflammation and deposition of extracellular
matrix proteins. The best studied adipokines are adiponectin and leptin. Adiponectin protects against
hepatic inflammation and fibrogenesis, and leptin functions as a profibrogenic factor. These and other
adipokines are supposed to modulate disease severity in patients with liver cirrhosis. Consequently,
circulating levels of these proteins have been analyzed to identify associations with parameters of
hepatic function, portal hypertension and its associated complications in patients with liver cirrhosis.
This review article briefly addresses the role of adipokines in hepatitis and liver fibrosis. Here, studies
having analyzed these proteins in systemic blood in cirrhotic patients are listed to identify adipokines
that are comparably changed in the different cohorts of patients with liver cirrhosis. Some studies
measured these proteins in systemic, hepatic and portal vein blood or after TIPS to specify the tissues
contributing to circulating levels of these proteins and the effect of portal hypertension, respectively.
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1. Introduction
Liver cirrhosis is a severe disease whose underlying etiologies are mostly alcohol abuse, chronic
hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, as well as non-alcoholic steatohepatitis
(NASH) [1]. NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD), whose
prevalence is steadily increasing because of the obesity epidemic [1,2].
High fat diets, Western-type diets, diets enriched in fructose and light to moderate alcohol intake
could trigger the onset and progression of NAFLD [3–5]. Excess dietary fructose is connected to
hepatic ATP depletion in type 2 diabetes patients and thus may contribute to NAFLD pathogenesis [6].
In patients with chronic HCV, daily intake of industrial fructose is linked to severe liver fibrosis [7].
Obesity per se raises the risk for decompensation of liver cirrhosis irrespective of the underlying
etiology [8]. This is partly explained by the obesity-related rise of portal pressure [8]. Weight loss in
overweight patients with liver cirrhosis though lowers portal pressure and possibly improves liver
function [8,9].
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Malnutrition and sarcopenia are further complications of liver cirrhosis patients and are relatively
common in advanced disease [10]. Mortality risk, development of hepatic decompensation and
secondary complications of liver cirrhosis are high in these patients [11,12].
Associations of obesity and malnutrition with severity of liver cirrhosis suggest that adipose
tissue may have an impact on disease pathophysiology. Shifting lipid storage from subcutaneous to
visceral fat tissues is well known to be associated with liver damages [13]. Functional differences of
subcutaneous and visceral adipose tissue are associated with changes in their adipokine profiles [14,15]
and possibly distinct levels of these adipokines in the portal and systemic blood [16]. We are, however,
unaware of studies showing adverse effects of excess visceral fat mass on hepatic function in patients
with liver cirrhosis.
Age of the patients seems to be also relevant for fibrosis progression. Elderly patients more
likely have NASH and advanced liver fibrosis compared to younger NAFLD patients [17]. In older
HCV-infected patients, an accelerated progression of fibrosis has been documented [18].
Gender affects the incidence and progression of liver diseases. Females are more susceptible
to toxic insults like alcohol, but less often develop decompensated disease when infected with
HCV [19,20]. Male gender is even a risk factor for NAFLD [21]. The likelihood of males to die
from chronic liver disease or cirrhosis is two-fold higher compared to females [22].
The one-year mortality of patients with liver cirrhosis is 1% and may rise up to 57% in those with
decompensated liver disease and complications [23]. The Child-Pugh or Child-Turcotte-Pugh score was
established to predict risk in patients with liver cirrhosis upon insertion of a transjugular intrahepatic
portosystemic shunt (TIPS) and is widely used to assess liver dysfunction. This score considers ascites,
encephalopathy, total bilirubin, albumin and international normalized ratio (INR) [24,25]. The model
for end-stage liver disease (MELD) score has been primarily developed to assess the survival of patients
undergoing TIPS. The MELD score is calculated from total bilirubin, creatinine and INR values and is
used for liver transplant priority ranking [24,26].
Serious complications of liver cirrhosis are ascites, variceal bleeding, hepatic encephalopathy
and, most fatally, hepatorenal syndrome. Intrahepatic resistance and splanchnic vasodilation account
for portal hypertension, which is the major cause of these sequelae [1,27]. Intestinal translocation of
bacteria in advanced liver disease contributes to the hyperdynamic circulation [27,28] and spontaneous
bacterial peritonitis, which may advance to sepsis and hepatic encephalopathy [1,27,28]. Liver cirrhosis
of any cause is a risk factor for hepatocellular carcinoma, and increasing age, male gender, obesity and
insulin resistance contribute to its development and progression [29].
Abnormal glucose metabolism is frequently diagnosed in liver cirrhosis [30]. Hyperinsulinemia,
insulin resistance and raised hepatic glucose production are common in those patients [31]. Insulin
resistance contributes to hepatic decompensation in the cirrhotic patient [32]. TIPS alleviate
hepatic insulin clearance, thereby augmenting hyperinsulinemia, which may further worsen glucose
homeostasis [33].
Body weight, fat free mass and muscle strength improve after TIPS [33,34]. Reversal of portal
hypertension by TIPS is supposed to contribute to weight gain, but the underlying mechanisms are
still unknown [34].
Adipokines are well known to regulate liver function. Circulating levels of adipokines are mostly
altered in patients with liver cirrhosis and are partly related to MELD and/or Child-Pugh score.
These associations are exciting and point to a functional role of adipokines in the pathophysiology of
liver cirrhosis and its complications. The present review article summarizes studies having analyzed
associations of systemic adipokine levels with the severity of liver cirrhosis.
2. Adipokines in Liver Cirrhosis
Various adipokines affect hepatic function, and only a few of them have been discussed in this
review article. Adiponectin and leptin are the most studied adipokines so far, and various reports
on their effects in the liver have been published [35,36]. Omentin, as well as adiponectin are reduced
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in obesity, while most, if not all, other adipokines are induced, and this indicates a specialized role
of those proteins [2,37]. Galectin-3 is a well-described profibrotic factor and most likely contributes
to liver injury in cirrhosis [38]. Interleukin-6 is an extensively analyzed cytokine and an acute phase
protein regulating inflammatory responses [39,40]. Resistin seems to reflect macrophage activation
in humans and, therefore, is supposed to be changed in liver cirrhosis [41]. Cirrhosis is a risk factor
for hepatic carcinogenesis, which is blocked by chemerin. Altered levels of this chemokine in liver
cirrhosis may predispose to tumor development [35,42]. Numerous studies have been published
where systemic levels of these adipokines were analyzed in patients with liver cirrhosis to identify
associations with disease severity and secondary complications, and we are unaware of a review
article summarizing these results. The intention of the present work was to list these investigations
to realize which of these proteins are concordantly changed in different cohorts of cirrhosis patients.
Cross-sectional studies do not permit any functional conclusions, and preclinical studies on the role of
adipokines in liver cirrhosis are sparse. Though we speculate about the pathophysiological function of
these adipokines in liver cirrhosis, many issues are still unresolved.
2.1. Adiponectin
2.1.1. General Information
Adiponectin is a 28-kD protein almost exclusively secreted by adipocytes. High adiponectin levels
circulate in serum and are reduced in obesity. Adiponectin ameliorates insulin sensitivity, and thus,
lower serum levels are correlated with disturbed glucose metabolism. Adiponectin is an antisteatotic,
anti-inflammatory and antifibrotic adipokine (Figure 1), and low levels may predispose to fatty liver
and advanced hepatic injury [2].
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Hepatic stellate cells are the main profibrotic cells in the liver. These cells become activated 
upon liver injury and start to proliferate and produce extracellular matrix proteins. Adiponectin 
reduces hepatic stellate cell activation, proliferation and survival [43,44]. Connective tissue growth 
factor is one of the profibrotic cytokines released by hepatocytes and is reduced by adiponectin [45]. 
Figure 1. Summary of the hepatic effects of the adipokines adiponectin, leptin, chemerin and omentin
in the liver (inner ellipse). ⇑ indicates a positive and ⇓ a negative effect on the respective pathways.
The text at the outer ellipse tells whether systemic levels of these adipokines are induced or reduced in
patients with liver cirrhosis compared to controls. “Controversial” indicates that contradictory findings
have been published so far.
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Hepatic stellate cells are the main profibrotic cells in the liver. These cells become activated upon
liver injury and start to proliferate and produce extracellular matrix proteins. Adiponectin reduces
hepatic stellate cell activation, proliferation and survival [43,44]. Connective tissue growth factor is
one of the profibrotic cytokines released by hepatocytes and is reduced by adiponectin [45]. Beneficial
activities of this adipokine in the liver have been thoroughly summarized in recent review articles,
which are recommended for further reading [2,46–48].
Because it is not feasible to raise circulating adiponectin in humans, present investigations test
the suitability of adiponectin analogues. These agents attenuate liver fibrosis in animal models [49,50].
Thioacetamide-induced activation of hepatic stellate cells and liver resident macrophages are
markedly suppressed, suggesting that these molecules have the potential to become new anti-fibrotic
therapeutics [50].
Adiponectin receptors 1 and 2 are expressed in most cells and tissues, and ceramidase becomes
activated upon binding of adiponectin [51,52]. Downstream targets of adiponectin, which may be
activated by metabolites derived from ceramidase activity, are adenosine monophosphate -activated
protein kinase and peroxisome proliferator-activated receptor α [51–53]. Both are well characterized
concerning their hepatoprotective activities [54,55].
Adiponectin is cleared from the circulation primarily by the liver. Female humans and rodents
have higher plasma adiponectin levels than males. Clearance rate is, however, comparable in both
sexes, suggesting that systemic levels are defined by adiponectin production in fat tissues [56].
Different adiponectin multimers circulate in serum. Trimers, hexamers and high molecular weight
(HMW) forms have been identified, with beneficial effects in metabolism being attributed to the latter
form [2].
2.1.2. Circulating Adiponectin in Liver Cirrhosis
Various studies have analyzed whether systemic adiponectin is changed in patients with liver
cirrhosis when compared to patients with chronic liver disease or healthy-liver controls (Table 1).
Increased systemic adiponectin in the cirrhotic patients has been identified in all of the studies
(Table 1) [57–63]. Importantly, elevated adiponectin is found in the patients independent of disease
etiology (Table 1) [57–65]. Higher adiponectin was identified in normal-weight and overweight
patients independent of the age of the participants in each cohort (Table 1). Interestingly, there
are no associations of serum adiponectin with the homeostasis model assessment (HOMA) index,
as a surrogate marker of insulin sensitivity [59,61] or body mass index (BMI) [63,65] in cirrhosis
patients. High adiponectin even increases the risk to develop hepatocellular carcinoma in HCV-infected
patients [66] suggesting that the well-characterized hepatoprotective and anti-carcinogenic effects of
this adipokine are blocked [2,67].
In rats with liver fibrosis, HMW adiponectin is the only isoform found increased in serum [68].
In HCV-infected patients, total and HMW adiponectin are higher in cirrhosis [64,66]. Here, total, but
not HMW serum adiponectin levels positively correlate with histologically scored liver fibrosis and
inflammation [64]. Additional studies are required to elucidate the distribution of adiponectin isoforms
in liver cirrhosis patients.
Elevated serum adiponectin is also found in patients with rheumatoid arthritis, inflammatory
bowel disease and type 1 diabetes [69–71]. Impaired elimination from the circulation, higher release
from fat tissues eventually stimulated by disease-associated hormones or drugs have all been
discussed to contribute to raised serum adiponectin [70]. Up to now, neither the source, nor the
pathophysiological role of elevated adiponectin have been unraveled.
Only one study has compared adiponectin in patients with non-cirrhotic and cirrhotic chronic
liver disease and demonstrates increased levels in the latter group [72] (Table 1). Adiponectin is
further positively associated with Child-Pugh stage and/or MELD score [57–60,63,65] (Table 1). This
principally indicates that high adiponectin is indeed related to liver cirrhosis and further suggests that
the liver has a central function in the excretion of adiponectin.
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Table 1. Adiponectin levels in ten different cohorts of patients with liver cirrhosis. Cohort size, % males,
age, body mass index (BMI) and disease etiology are listed. Numbers are given as the mean ± standard
deviation or standard errors of the mean (SEM), which is indicated. Data are also presented as median
and range (according to the respective publications cited). ↑ indicates that systemic levels are higher in
the liver cirrhosis patients than the healthy controls (HC) or patients with chronic liver disease (CLD).
Table also lists the associations of serum adiponectin with the Child-Pugh score and/or model for
end-stage liver disease (MELD) score. n.d., not described; HCV, hepatitis C virus.
Number of
Patients
(% Male)
Age (Years) BMI (kg/m2) Etiology
Systemic
Levels
Positive Associations with
Scores Reference
147 (73) 49.6 ± 11.9 n.d. Alcohol ↑ HC MELD, Child-Pugh [60]
45 (64) 57 28.1 Mixed ↑ HC n.d. [57]
38 (68) 63 ± 15.5 21.9 ± 2.7 Mixed ↑ HC Child-Pugh [62]
87 (51) n.d. n.d. Mixed ↑ HC Child-Pugh [59]
40 (75) 53.3 ± 8.2 27.9 ± 4.3 HCV ↑ HC n.d. [61]
20 (75) 47.6 ± 2.4 (SEM) 23.0 ± 0.6 (SEM) Mixed ↑ HC Child-Pugh [63]
79 (60) 66.6 ± 8.9 22.3 ± 2.9 HCV ↑ HC Child-Pugh [58]
40 (88) 59 (37–75) 25.89 (20.1–39.3) Alcohol n.d. Child-Pugh [65]
93 (59) n.d. n.d. Mixed ↑ CLD Highest in Child-Pugh B [72]
36 (64) 53.0 ± 1.3 (SEM) 27.1 ± 1.2 (SEM) HCV ↑ HC n.d. [73]
Similar concentrations of adiponectin in a peripheral vein, the portal vein and the hepatic vein
do not support this suggestion [59,74] (Table 2). However, when also considering the blood flow,
hepatic adiponectin extraction declines in parallel with the clinical stage of liver cirrhosis [63]. Bile
duct ligation in mice increases serum adiponectin, and this may further point to biliary excretion of this
protein [72,75]. In cholestatic patients with liver cirrhosis, higher and unchanged adiponectin is found
compared to cirrhotic controls [61,72]. Adiponectin is nevertheless detected at high levels in human
bile [72], indicating that the impaired biliary excretion route in liver cirrhosis patients contributes to its
raised serum levels.
Body cell mass defined by bio-electrical impedance analysis is a measure of the
metabolically-active body tissues [34]. TIPS placement leads to an increase of body cell mass and
serum adiponectin. Whether raised adiponectin is indicative for worsened hepatic clearance after TIPS
needs further study [76].
Esophageal varices are common complications in liver cirrhosis and are diagnosed by endoscopic
techniques. Non-invasive biomarkers to predict varices may help to reduce the number of screening
endoscopies [77]. A score calculated from platelet count, HOMA-insulin resistance (HOMA-IR) and
adiponectin predicts esophageal varices with a high sensitivity and specificity [78]. Whether this
approach is suitable in clinical practice needs further analysis.
Higher adiponectin in patients with liver cirrhosis and ascites compared to those without ascites
has been described in some [60,65], but not all studies [61]. Ascites mostly develops in patients with
more advanced liver dysfunction [65], and this may partly explain raised adiponectin in those patients.
Serum adiponectin is about five-fold higher when compared to levels in ascites [79]. This excludes
excess adiponectin production in ascites to contribute to serum levels.
Though adiponectin is markedly elevated in cirrhosis and positively correlates with MELD and
Child-Pugh score, it is not a suitable biomarker to predict overall survival [65].
Circulating adiponectin is increased in patients with liver cirrhosis independent of disease etiology,
age or BMI. Most studies have identified positive associations with Child-Pugh or MELD score
and impaired biliary excretion of adiponectin may be one pathway contributing to this correlation.
Increased adiponectin in liver cirrhosis does not seem to exert any protective effects. This may be
because of downregulation of the respective receptors in the cirrhotic liver [75,80]. In advanced NASH,
a negative association of serum adiponectin and liver fat content has been identified, suggesting that
this adipokine contributes to hepatic lipid waste [81]. Adiponectin may, therefore, also have a role in
fat loss and hypermetabolism in liver cirrhosis [82].
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Table 2. Adipokine levels in systemic venous serum (SVS), hepatic venous serum (HVS) and portal
vein (PVS) blood of different cohorts with liver cirrhosis. Similar levels of adiponectin in those
compartments were described in two studies [59,74]. There is one report showing splanchnic extraction
of this adipokine, but levels in the different compartments were not presented [63]. Therefore, this
study is not listed. n.d., not described; ≈ indicates similar levels in those compartments; ↑ indicates
increased levels compared to the other compartments labeled with the identical upper case number
(a, b); Interleukin6 (IL-6).
Adipokine Cohort Size(% Male) Age (Years) BMI (kg/m
2) Etiology SVS HVS PVS References
Adiponectin 11 (n.d.) n.d. n.d. Viral ≈ ≈ ≈ [59]
Adiponectin 50 (78) 55 ± 2 25.5 ± 0.9 Mostly alcoholic ≈ ≈ ≈ [74]
Chemerin 45 (80) 54 (26–81) n.d. Mostly alcoholic ≈ ↑ a ≈ a [83]
Leptin 50 (78) 55 ± 2 25.5 ± 0.9 Mostly alcoholic ↑ a ≈ a ≈ a [74]
Omentin 40 (80) 52 (26–81) 26.0 (16–38) Mostly alcoholic ≈ ≈ a ↑ a [84]
Resistin 50 (78) 55 ± 2 25.5 ± 0.9 Mostly alcoholic ≈ ≈ ≈ [74]
Galectin-3 33 (75.8) 49 (40–81) 25.6 (17–38) Alcoholic ≈ ↑ a ≈ a [85]
Visfatin 50 (78) 55 ± 2 25.5 ± 0.9 Mostly alcoholic ≈ a,b ↑ a ↑ b [74]
IL-6 41 (78) n.d. n.d. Mostly alcoholic ↑ a,b ≈ a,b ↑↑ a [86]
2.2. Chemerin
2.2.1. General Information
Chemerin is an attractant for immune cells and is highly expressed in adipocytes and
hepatocytes [87–89]. Chemerin is released by the cells as an inactive (18 kD) proprotein.
Carboxy-terminal processing by proteases produces isoforms that lack six (Chem157), eight (Chem155)
or nine (Chem154) amino acids. Among these truncated proteins, Chem157 is most active in recruiting
immune cells [90]. Chem157 is commercially available as a recombinant protein and is the best
studied isoform. The biologic function of additional chemerin variants has not been clarified yet [87].
Chemerin may act as a pro- or anti-inflammatory mediator dependent on the equilibrium of its different
isoforms [87,90,91] (Figure 1). Receptors for chemerin are chemokine-like receptor 1 (CMKLR1),
G-protein coupled receptor 1 (GPR1) and CC-motif chemokine receptor-like 2 (CCRL2). The latter is a
non-signaling molecule that binds chemerin to increase its local bioactivity [90].
Chemerin and its receptor CMKLR1 are expressed in hepatocytes and hepatic stellate cells [89,92].
Though chemerin may exert autocrine and/or paracrine activities in the liver, its function in this organ
is still unclear. Indeed, chemerin, GPR1 and CMKLR1 knock-out mice do not display gross hepatic
abnormalities even when fed diets to produce obesity or NAFLD [93–95]. Chemerin and GPR1 seem
to stimulate insulin secretion and knock-out animals consequently display hyperglycemia [94,95]. One
study has shown that hepatic overexpression of chemerin in mice impairs skeletal muscle, but not
hepatic insulin response [96].
Circulating chemerin is raised in obesity, which is mediated by higher synthesis in fat
tissues [87,97]. The bulk of human studies indicate associations of chemerin with the metabolic
syndrome [87,91,98,99]. Indeed, positive associations of circulating chemerin with BMI, fat mass
and markers of insulin resistance have been identified [87]. Of note, while total chemerin serum
levels are raised in obesity, the portion capable of activating CMKLR1 is unchanged. The underlying
mechanisms have not been resolved yet, and enhanced removal of active chemerin isoforms and/or
impaired processing of prochemerin may be involved [100]. In serum of obese humans, relatively
short chemerin isoforms have been recently detected. Whether these short forms are derived from
chemerin degradation and exert any biologic activity is not well investigated [101].
Measurement of chemerin in murine and human body fluids by enzyme-linked immunosorbent
assays does not distinguish the different chemerin isoforms, though their distribution may be changed
in the patients [100].
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Serum chemerin is raised in HCV infected patients, but is not related to HOMA-IR or liver
fibrosis [102]. In NAFLD patients, both higher and unchanged serum chemerin levels have been
reported [91]. This principally excludes a strong association of chemerin in serum and hepatic function.
2.2.2. Circulating Chemerin in Liver Cirrhosis
To the best of our knowledge, there are only two studies having analyzed systemic chemerin
in liver cirrhosis patients (Table 3). In one study, patients with mostly HCV-induced cirrhosis and
hepatocellular carcinoma were enrolled. The second study included patients with mainly alcoholic
liver cirrhosis [83,103].
Table 3. Chemerin levels in patients of two cohorts with liver cirrhosis. Number of patients, % males,
age, body mass index (BMI) and disease etiology are listed. Numbers are given as median and range.
Studies did not compare systemic levels of patients and respective control cohorts. The table lists
associations of systemic chemerin with the Child-Pugh score. n.d., not described; HCV, hepatitis
C virus.
Number of
Patients
(% Male)
Age (Years) BMI (kg/m2) Etiology
Systemic
Levels
Negative
Associations
with Scores
Reference
44 (66) 71 (50–82) 22.5 (15.6–33.5) Mostly HCV n.d. Child-Pugh [103]
45 (80) 54 (26–81) n.d. Mostly alcohol n.d. Child-Pugh [83]
The obesity and diabetes related parameters BMI, fasting plasma glucose levels, fasting insulin
levels, hemoglobin A1c and HOMA-IR do not correlate with chemerin in serum [103]. Both studies
describe a negative association of serum chemerin with the Child-Pugh score [83,103]. Chemerin
in serum does not correlate with the MELD score, albumin, bilirubin, aspartate aminotransferase,
alanine aminotransferase and fibrinogen in one study [83]. The second analysis identified positive
correlations with platelet counts and albumin and negative associations with bilirubin and alanine
aminotransferase [103]. The two studies agree that serum chemerin is positively associated with
prothrombin time [83,103]. This suggests that serum chemerin is related to coagulation rather than liver
function in the patients. Indeed, chemerin is similar in patients with compensated and decompensated
liver cirrhosis in a subgroup of patients with normal prothrombin time [83].
Serum chemerin is not related to variceal size or ascites. Portal vein chemerin is nevertheless
higher in patients with ascites. This may resemble elevated release from omental fat depots and/or
reduced hepatic uptake [83].
In the liver, hepatocytes are the main producers of chemerin. Protein is also released by hepatic
stellate cells [89]. Hepatic vein chemerin in liver cirrhosis is higher than portal vein concentrations,
demonstrating enhanced synthesis and secretion by the liver cells [83] (Table 2).
The function of chemerin in the liver has not been studied in more detail. Chemerin inhibits
the growth of liver tumors [42], and prospective studies may identify an association of low serum
chemerin and the development of hepatocellular carcinoma. Future experiments should focus on the
physiological and pathophysiological roles of chemerin isoforms in the circulation and the liver.
2.3. Leptin
2.3.1. General Information
Leptin is a 16-kD hormone that regulates satiety and energy expenditure. Mutations in the leptin
gene or the leptin receptor gene contribute to obesity. Serum leptin is nevertheless raised in the
obese who display leptin resistance in the hypothalamus [104]. Pleiotropic effects of leptin have been
identified. This hormone regulates the immune system, hematopoiesis, angiogenesis, reproduction
and carcinogenesis among others [35,105,106].
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Moreover, leptin is known to contribute to fibrogenesis in chronic liver diseases. Leptin is a
mitogen for activated hepatic stellate cells and further enhances the synthesis of inflammatory and
profibrogenic factors in these cells. It increases transforming growth factor β synthesis in Kupffer cells,
which promotes fibrosis progression. Activated hepatic stellate cells are capable of producing leptin,
and this is supposed to augment hepatic damage [35,107–109] (Figure 1).
Various review articles have been published summarizing the inflammatory and profibrogenic
effects of leptin in the liver [44,46,110]. Therefore, these issues are not further addressed herein.
2.3.2. Circulating Leptin in Liver Cirrhosis
Systemic leptin is higher in healthy females, and this also applies for patients with liver
cirrhosis [111,112]. Gender-related differences were not described in all studies or were simply
not calculated because of the small number of patients enrolled or the similar distribution of males and
females in the respective cohorts [113–115]. Though some investigations show comparable changes
of leptin levels in both sexes, other investigations have identified gender-related differences [60,112].
In one study, leptin is only raised in female cirrhotic patients, while a separate analysis has found
decreased levels in female, but not male patients [60,112] (Table 4).
Several studies report that leptin is increased in patients with liver cirrhosis [111,112,116]. Separate
investigations have shown reduced leptin levels in the cirrhotic patients [60,113]. Further, unchanged
circulating leptin in cirrhotic patients has been also described [73,114]. Discordant findings are not
related to disease etiology (Table 4). It is important to note that all of the studies listed in Table 4 have
enrolled healthy controls. Thus, it is not clear whether leptin is further changed in liver cirrhosis when
compared to non-cirrhotic patients with chronic liver diseases.
Though positive associations of leptin with HOMA-IR have been identified [117], this adipokine
does not correlate with blood glucose and insulin [114]. Accordingly, impaired glucose tolerance and
type 2 diabetes are not linked to changes in leptin levels [118].
Systemic leptin positively correlates with BMI in patients with liver cirrhosis [114,115,117].
Malnourished cirrhotic patients have lower serum leptin than appropriately-nourished patients [117].
This suggests that anthropometric variables and nutritional status are closely associated with serum
leptin and have to be considered when analyzing systemic leptin levels in patients with liver cirrhosis.
Several studies investigated whether circulating leptin levels are correlated with severity of
liver dysfunction. Here, raised leptin has been identified in male patients with a higher Child-Pugh
score [119]. A separate study describes a transient increase of serum leptin in early stages of liver
disease, which normalize in those patients with advanced disease [120]. No associations of leptin and
Child-Pugh score [111,114] and lower levels in patients with hepatic decompensation [118] have been
also reported (Table 4).
Discordant findings on leptin levels in liver cirrhosis patients indicate that this adipokine is
closely linked to BMI and nutritional state rather than hepatic function. Indeed, after adjusting for
BMI, serum leptin is not associated with disease severity in non-diabetic patients with alcoholic
liver cirrhosis [65]. A prospective, multicenter, uncontrolled pilot study enrolled patients with a
BMI ≥ 26 kg/m2, compensated liver cirrhosis and portal hypertension. The intensive 16-week
lifestyle intervention program decreased body weight, portal hypertension and systemic leptin levels.
Child-Pugh scores and MELD scores were not improved, arguing against a close relationship between
systemic leptin levels and clinically-scored disease activity [8].
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Table 4. Leptin levels in different cohorts of patients with liver cirrhosis. Cohort size, % males, age,
body mass index (BMI) and disease etiology are listed. Numbers are given as the mean ± standard
deviation, or the standard errors of the mean (SEM), or as the median and range. ↑ indicates higher
and ↓ lower systemic levels compared to the controls, and all studies enrolled healthy control cohorts.
The table also lists associations of serum leptin with the Child-Pugh score. n.d., not described; HBV,
hepatitis B virus; HCV, hepatitis C virus.
Number of
Patients
(% Male)
Age (Years) BMI (kg/m2) Etiology
Systemic
Levels
Associations with
Score Reference
107 (100) 49.8 ± 11.5 n.d. Alcohol Unchanged No [60]
24 (66) 64 (64–75) 21.3 (17.3–26.9) HCV Unchanged No [115]
13 (0) 56.1 ± 7.4 22.6 ± 4.4 Alcohol Unchanged No [119]
54 (56) 55.5 (38.3–72.8) 26.6 (20.6–32.7) Mixed n.d. Child-Pugh negative [118]
36 (64) 53.0 ± 1.3 (SEM) 27.11 ± 1.18 (SEM) HCV Unchanged n.d. [73]
40 (55) 57 ± 11 n.d. Mixed Unchanged No [114]
18 (100) 45 ± 1.5 (SEM) 24.2 ± 0.8 (SEM) Alcohol Unchanged No [112]
40 (88) 59 (37–75) 25.89 (20.1–39.3) Alcohol n.d. No [65]
26 (100) 59 (47–72) 23.7 (21.9–25.5) Mixed ↑ No [116]
10 (0) 44 ± 3.7 (SEM) 26.4 ± 2.2 (SEM) Alcohol ↑ No [112]
35 (49) 53 (28–73) 24 (18–33) HBV/HCV ↑ No [111]
24 (100) 51.7 ± 10.6 22.3 ± 4.0 Alcohol ↑ Child-Pugh positive [119]
24 (48) 45.5 ± 8.0 n.d. HBV, HDV ↓ No [113]
40 (0) 48.8 ± 9.9 n.d. Alcohol ↓ No [60]
Leptin is neither changed in patients with ascites, nor in those with esophageal
varices [60,65,78,119]. A relation of circulating leptin with hepatic encephalopathy, cholestasis and
renal disease has been excluded [60].
The cytokines interleukin-6 and -8 (IL-6, IL-8) and TNF in ascites are above serum levels [121].
Leptin is nearly two-fold more concentrated in ascites than in serum [74,122]. Positive correlations
of serum and ascites leptin levels indicate that ascites leptin contributes to systemic levels [74,122].
Though patients with liver cirrhosis and ascites have higher IL-6 and IL-8 in serum than those without
ascites [121], serum leptin is unchanged [65,119]. To what extent proteins found at high concentrations
in ascites do add to serum levels is not exactly known.
Subcutaneous fat releases two- to three-fold more leptin than visceral adipose tissues [123].
Accordingly, plasma leptin concentration is higher in the radial artery than the portal vein in very
obese subjects [16] and in patients with liver cirrhosis [74] (Table 2). Subcutaneous adipose tissue is the
major source of serum leptin, and this seems to also apply for patients with liver cirrhosis. Whether
leptin release from fat depots is changed in the patients or is even raised in intraabdominal adipose
tissues of those patients with ascites needs further clarification.
TIPS contribute to weight gain, and leptin may simultaneously increase. Higher body weight
after this intervention is, however, not consistently accompanied by raised leptin levels [76,124].
Altogether, serum leptin is mostly not associated with liver dysfunction. Compared to the healthy
liver controls, its levels are higher, lower or normal in patients with liver cirrhosis. Discordant findings
may be due to the close association of serum leptin with BMI and body fat mass.
2.4. Omentin
2.4.1. General Information
Omentin is a 30-kD protein, which is expressed by stromal-vascular cells in adipose tissue.
Interestingly, omentin is highly abundant in visceral fat [125]. In obesity, expression of omentin
declines in this adipose tissue depot, and circulating omentin is reduced [37,125]. Omentin is an
anti-inflammatory protein and further improves insulin sensitivity [125,126] (Figure 1). Whether
omentin directly regulates the biologic function of liver cells has not been clarified yet.
Omentin induces vasodilation and angiogenesis partly by activating endothelial nitric oxide
synthase [127,128]. Inappropriate levels of nitric oxide contribute to splanchnic vasodilation and
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hepatic vasoconstriction and consequently portal hypertension [129]. Portal hypertension leads to the
serious complications of liver cirrhosis, such as ascites, bleeding from varices, encephalopathy and
renal dysfunction [130].
2.4.2. Circulating Omentin in Liver Cirrhosis
Omentin levels tend to be higher in patients with liver cirrhosis compared to healthy-liver
controls [84] (Table 5). In HCV-infected patients, serum omentin is increased. Neither hepatic omentin
mRNA, nor its serum levels are associated with features of liver injury [131]. No differences in omentin
serum levels regarding the severity of liver cirrhosis evaluated by the Child-Pugh or MELD scores
have been identified [84,132] (Table 5). There are no changes in patients with ascites or varices [84].
Table 5. Omentin levels in the patients of two cohorts with liver cirrhosis. Number of patients, % males,
age, body mass index (BMI) and disease etiology are listed. Numbers are given as median and range. ↑
indicates higher systemic levels compared to the healthy controls (HC). There are no associations of
systemic omentin with Child-Pugh and MELD scores. n.d., not described.
Number of
Patients
(% Male)
Age (Years) BMI(kg/m2) Etiology
Systemic
Levels
Associations
with Scores Reference
40 (80.0) 52 (26–81) 26 (16–38) Mostly alcohol ↑ HC trend No [84]
51 (68.6) 52 (26–80) 27 (17–40) Mixed n.d. No [132]
In agreement with its preferred synthesis in intra-abdominal fat depots, portal vein omentin is
higher than the hepatic vein level in healthy-liver controls and cirrhotic patients [84,125] (Table 2).
Of note, omentin is induced in the portal vein of the patients compared to the controls, and this
may reflect raised release from intraabdominal fat and/or impaired hepatic clearance. Portal vein
omentin does neither correlate with hepatic venous pressure gradient, nor complications of portal
hypertension [84].
Circulating omentin in liver cirrhosis has been analyzed in two relatively small cohorts of patients
so far. Both studies agree that omentin is not associated with severity of liver cirrhosis.
2.5. Galectin-3
2.5.1. General Information
Galectin-3 is a 30-kD protein expressed by various cells including immune cells and
adipocytes [133,134]. Visceral human fat displays higher galectin-3 levels than subcutaneous adipose
tissue. Hepatic galectin-3 is induced in obesity [134], and systemic galectin-3 is increased [135].
Galectin-3 exerts various biological functions and regulates cell death, inflammation, angiogenesis
and collagen synthesis (Figure 2). Blockage of galectin-3 prevents activation of hepatic stellate
cells and, accordingly, expression of collagen. Loss of galectin-3 protects mice from fibrosis due
to carbon tetrachloride [136]. Hepatic formation of advanced lipoxidation end products contributes
to inflammation and fibrosis in NASH [137]. Galectin-3 mediates the uptake of these particles into
the liver, and mice deficient in galectin-3 are protected from hepatitis and fibrosis in high fat diet
models [136,138].
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Figure 2. This figure summarizes the hepatic effects of the adipokines resistin, interleukin-6, galectin-3
and visfatin in the liver (inner ellipse). ⇑ indicates a positive and ⇓ a negative effect on the respective
pathways. The text at the outer ellipse is related to the respective levels in serum of patients with liver
cirrhosis. “Controversial” means that contradictory findings have been published so far.
Macrophages and cholangiocytes express galectin-3 in the healthy liver. In cirrhotic liver,
galectin-3 is further detected in hepatocytes [85,139], suggesting raised hepatic galectin-3 production
in liver cirrhosis.
In a model of thioacetamide-induced liver injury, in murine NASH and in NASH patients,
inhibition of galectin-3 improves hepatic inflammation, cell death and fibrosis [38,133,140].
2.5.2. Circulating Galectin-3 in Liver Cirrhosis
Serum galectin-3 is increased in patients with liver cirrhosis compared to the healthy controls and
non-cirrhotic patients with chronic liver disease [85,141,142] (Table 6). Levels are higher in the patients
with alcoholic cirrhosis than in patients with non-alcoholic cirrhosis mostly due to HCV [141]. In a
separate study, HCV-infected patients had higher galectin-3 than patients with alcoholic or cryptogenic
cirrhosis [85]. A third study compared HBV- and HCV-caused cirrhosis and described increased
galectin-3 in the latter cohort [142].
Galectin-3 is positively associated with the Child-Pugh score, and levels are highest in patients
classified as C [85,141]. Positive correlations of galectin-3 and MELD score have been described in
patients with alcoholic liver cirrhosis [85] (Table 6). Galectin-3 is already elevated in patients with little
ascites, but does not further increase in parallel with ascites volume [85].
In healthy-liver controls, galectin-3 is higher in portal venous serum compared to hepatic venous
serum and systemic levels, which is principally in line with higher expression in intra-abdominal fat
depots [135]. In liver cirrhosis patients, this distribution is changed, and galectin-3 concentrations are
higher in the hepatic vein than the portal vein blood [85] (Table 2). This is in accordance with raised
hepatic expression of galectin-3 in the fibrotic liver [85].
Galectin-3 in serum is increased in liver cirrhosis and is positively associated with Child-Pugh
and MELD scores. Levels may be further affected by the etiology of liver cirrhosis, but this needs
further analysis. Galectin-3 is a profibrotic protein and, thus, most likely contributes to liver injury in
patients with cirrhosis [38].
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Table 6. Galectin-3 levels in patients of three cohorts with liver cirrhosis. Cohort size, % males, age,
body mass index (BMI) and disease etiology are listed. Numbers are given as the mean ± standard
deviation or as the median and range. ↑ indicates higher systemic galectin-3 levels compared to the
controls. The table also lists associations of serum galectin-3 with Child-Pugh and model for end-stage
liver disease (MELD) scores. n.d., not described; HC, healthy-liver controls; HBV, hepatitis B virus;
HCV, hepatitis C virus; CLD, non-cirrhotic chronic liver disease.
Number of
Patients
(% Male)
Age (Years) BMI(kg/m2) Etiology Serum Levels
Positive Associations
with Scores Reference
87 (n.d.) n.d. n.d. Mostly alcohol ↑, HC Unchanged CLD Child-Pugh [141]
22 (55) 63.5 ± 10.8 n.d. HBV/HCV ↑, CLD n.d. [142]
33 (76) 49 (40–81) 25.6 (17–38) Alcohol ↑, HC Child-Pugh MELD [85]
2.6. Resistin
2.6.1. General Information
Resistin is a 12-kD protein and has been discovered as an adipokine in rodents. In the animals’
serum, resistin is consistently higher in obesity, and there is a clear relationship between resistin
levels and insulin resistance. In mice fed a high fat diet, normalization of resistin levels by antisense
oligonucleotides reverses hepatic insulin resistance [41,143].
In humans, macrophages express and release this protein, and these cells are supposed to be the
major source of serum resistin [41].
Adipokines that are expressed and secreted in higher quantity from visceral fat may be increased
in the portal vein when compared to systemic levels [16]. These proteins are supposed to contribute to
the metabolically-harmful effects of visceral adiposity [14]. Resistin is not raised in the portal vein,
arguing against higher release from macrophages in intra-abdominal adipose tissues of humans [16].
Conflicting results regarding elevated systemic resistin levels in human obesity and associations
with insulin resistance have been published [41]. Case-control studies have nevertheless shown that
baseline serum resistin levels are associated with the risk to develop type 2 diabetes [144].
Liver macrophages are activated upon hepatic injury and are involved in the development of
inflammation and fibrosis [145]. Resistin expression is indeed raised in the fibrotic human liver [146].
In human NASH liver, Kupffer cells and hepatic stellate cells express resistin, which also predicts
fibrosis severity [147]. In hepatic stellate cells, resistin is shown to induce monocyte chemoattractant
protein-1 and IL-8 [146]. This protein further mediates proliferation of these cells and suppresses
apoptotic cell death [148]. Resistin upregulates the class A scavenger receptor in macrophages, which
contributes to uncontrolled lipid uptake [149]. Downregulation of the hepatic low-density lipoprotein
(LDL) receptor [150] and stimulation of de novo lipogenesis in liver cells by resistin may further
contribute to dyslipidemia and liver steatosis [150]. This may add to insulin resistance, which has been
recently identified in resistin-incubated HepG2 cells [151] (Figure 2).
2.6.2. Circulating Resistin in Liver Cirrhosis
Resistin is found increased in patients with liver cirrhosis even when compared to non-cirrhotic
patients with chronic liver injury. This is described in cirrhosis due to alcohol and viral
infections [58,60,74,152,153] (Table 7). Bahr et al. report that resistin is lower in liver cirrhosis caused
by viral infection when compared to alcoholic- and biliary-induced cirrhosis [152].
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Table 7. Resistin levels in six cohorts of patients with liver cirrhosis. Cohort size, % males, age, body
mass index (BMI) and disease etiology are listed. Numbers are given as the mean ± standard deviation
(not indicated), or the standard error of the mean (SEM), or as the median and range. ↑ indicates higher
systemic levels compared to the controls. The table also lists associations of serum resistin with the
Child-Pugh score. n.d., not described; HC, healthy controls; CLD, non-cirrhotic chronic liver disease;
hepatitis B virus, HBV.
Number of
Patients
(% Male)
Age (Years) BMI (kg/m2) Etiology
Serum
Levels
Positive
Associations Reference
147 (72.8) 49.6 ± 11.9 n.d. Alcohol ↑ HC No [60]
79 (59.5) 66.6 ± 8.9 22.3 ± 2.9 HCV ↑ HC Child-Pugh [58]
40 (87.5) 59 (37–75) 25.9 (20.1–39.3) Alcohol n.d. No [65]
57 47.5 ± 1.3 (SEM) 23.0 ± 0.4 (SEM) Mixed ↑ HC Child-Pugh [152]
50 (78) 55 ± 3 25.5 ± 0.9 Mostly alcohol ↑ HC Child-Pugh [74]
70 (60) 48.3 ± 11.1 n.d. HBV ↑ HC, ↑ CLD n.d. [153]
Resistin serum levels are positively associated with the Child-Pugh score in some, but not all
studies [58,60,74,152,153] (Table 7). Indeed, hepatic vein resistin is higher in Child-Pugh C than A
patients, suggesting increased secretion from the liver [74].
One of the studies could not demonstrate an association of resistin with liver dysfunction scores,
but here, resistin was higher in patients with cholestasis and patients with renal impairment [60].
Data on the association of systemic resistin with insulin resistance in patients with liver cirrhosis
are inconsistent [58,152].
Resistin is mostly expressed in macrophages and, accordingly, positively correlates with
inflammatory and profibrotic cytokines produced by these cells [154].
Resistin is not associated with portal hypertension and is not changed in patients with
ascites [65,152]. Ascites’ resistin is about two-fold higher when compared to systemic levels [79],
demonstrating that resistin production is raised in the peritoneal cavity.
In liver cirrhosis, resistin concentrations are comparable in the portal, hepatic and systemic
blood [74] (Table 2). This principally excludes that its synthesis is selectively induced in visceral fat,
the spleen, intestine or the liver.
Macrophage activation is a common feature of liver cirrhosis, which may be reflected by a rise
in serum resistin. This protein contributes to hepatic inflammation and fibrosis, indicating harmful
effects of higher circulating levels in liver cirrhosis [146,148].
2.7. Visfatin
2.7.1. General Information
Visfatin (nicotinamide phosphoribosyl-transferase, pre-B cell colony-enhancing factor) has a
molecular weight of about 55 kD and is a key enzyme in cellular nicotinamide adenine dinucleotide
biosynthesis. Cellular visfatin is low in NAFLD, thereby contributing to hepatocyte apoptosis [155].
Secreted visfatin functions as a multifunctional adipokine. Visfatin expression is induced in
adipose tissues of obese patients, and its systemic levels are increased in obesity [156]. Visceral and
subcutaneous adipose tissues express similar levels of visfatin [156,157]. Accordingly, portal vein,
hepatic vein and systemic visfatin concentrations are equal in patients with normal liver function [74].
Hepatocytes constitutively release visfatin [158], but these concentrations fail to markedly increase
levels in the hepatic vein [74].
The functions of secreted visfatin are manifold [159]. In hepatocytes, visfatin is shown to
upregulate glucose production [160]. Cultivation of hepatocytes in the presence of palmitate is
used as a model for liver steatosis. These cells release IL-6 and TNF in high quantity, and this is
further induced by visfatin [161] (Figure 2). In hepatic stellate cells synthesis of α-smooth muscle actin,
collagens and connective tissue growth factor are induced by visfatin, indicating profibrotic activity of
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this cytokine [162] (Figure 2). In line with this in vitro study, an in vivo analysis shows reduced hepatic
collagen and α-smooth muscle actin upon suppression of hepatic visfatin in tetracarbon chloride and
ethanol-treated rodents [163].
2.7.2. Circulating Visfatin in Liver Cirrhosis
One study has described reduced systemic and hepatic visfatin protein in patients with cirrhosis
when compared to healthy controls [164]. Strongly diminished visfatin in the circulation has been
also identified in a second analysis [74]. Separate studies in HBV-related cirrhosis show higher
circulating visfatin levels in patients with liver cirrhosis in relation to healthy controls and non-cirrhotic
HBV-infected patients [165,166] (Table 8).
Table 8. Visfatin levels in patients of five cohorts with liver cirrhosis. Cohort size, % males, age, body
mass index (BMI) and disease etiology are listed. Numbers are given as the mean ± standard deviation,
or the standard error of the mean (SEM), or as the median and range. ↑ indicates higher and ↓ lower
systemic levels compared to the controls. The table also lists associations of serum visfatin with the
Child-Pugh score. n.d., not described; HC, healthy controls; CLD, non-cirrhotic chronic liver disease;
HBV, hepatitis B virus.
Number of
Patients
(% Male)
Age (Years) BMI (kg/m2) Etiology
Serum
Levels Associations Reference
19 (68) 47.4 ± 2.5 (SEM) 23.0 ± 0.6 (SEM) Mixed ↓ HC No [164]
40 (87.5) 59 (37–75) 25.89 (20.08–39.31) Alcoholic n.d. No [65]
129 (77.5) 48.71 ± 11.65 22.86 ± 3.89 HBV ↑ HC, ↑ CLD n.d. [165]
50 (78) 55 ± 3 25.5 ± 0.9 Mostly alcoholic ↓ HC Child-Pugh positive [74]
153 (59.5) 42–60 n.d. HBV ↑ HC n.d. [166]
One study shows positive correlations with the Child-Pugh score, which has not been described
in further cohorts [65,74,164–166] (Table 8). Portal vein and hepatic vein visfatin are higher when
compared to systemic levels [74] (Table 2). This may indicate elevated release of visfatin from omental
fat and eventually the liver in cirrhotic patients. In consideration that low hepatic visfatin protein has
been detected in the cirrhotic liver [164], this issue is far from being well understood.
Visfatin in serum is not changed in those patients who develop ascites [65,79], and ascitic visfatin
levels are not related to the Child-Pugh score [79].
So far, only a few studies have reported on systemic visfatin in patients with liver cirrhosis, and
moreover, the data are conflicting.
2.8. Interleukin-6
2.8.1. General Information
Interleukin-6 (IL-6) is a 21-kD cytokine that is associated with inflammation. IL-6 is produced by
various cell types including adipocytes and immune cells [16,167]. Serum IL-6 is raised after infections
and in most inflammatory disorders including chronic liver diseases [167]. Chronically-increased IL-6
contributes to inflammation and suppresses insulin signaling [168]. On the other hand, IL-6 signaling
specifically in hepatocytes protects the animals from hepatic inflammation and insulin resistance [169]
(Figure 2). Hepatic IL-6 signaling induces the acute-phase response, which counteracts bacterial
infection and liver injury [40].
In a preclinical model of liver disease, mice pretreated with IL-6 have less hepatic injury [170].
Accordingly, hepatic dysfunction and hepatocyte death are aggravated in IL-6-deficient mice [171].
Loss of the IL-6 signal transducing molecule gp130 in non-parenchymal liver cells increases liver
fibrogenesis, while its deletion in hepatocytes is without any effect [40]. Lack of this receptor is linked
to pronounced bacterial growth after bile duct ligation and a higher mortality [172].
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Acute and chronic raise in IL-6 may exert opposing biologic activities. While short-time elevation
is mainly protective, chronically-increased levels are mostly related to harmful effects [36]. C-reactive
protein is one of the factors induced by IL-6 signaling in hepatocytes [16,173]. Portal vein IL-6 is
about 50% higher than levels in the radial artery and is positively correlated with serum CRP [16].
This clearly shows that IL-6 released by intra-abdominal adipose tissue is directly related to systemic
inflammation in the obese.
2.8.2. Circulating IL-6 in Liver Cirrhosis
Basically, most of the studies show increased systemic IL-6 in patients with liver
cirrhosis [39,40,153,174,175] (Table 9). Healthy probands and non-cirrhotic patients with chronic liver
disease served as controls. IL-6 levels are higher in alcoholic liver cirrhosis than in HCV or cryptogenic
cirrhosis [86,176,177] (Table 9). Ethanol increases gut permeability and bacterial translocation [178].
Monocytes of patients with alcoholic cirrhosis display an exacerbated response to lipopolysaccharide,
which is not observed in HCV-infected patients [179,180]. Thus, increased release of this cytokine by
peripheral and tissue resident macrophages seems to contribute to higher levels in alcoholic cirrhosis.
Further, serum IL-6 levels increase with a higher Child-Pugh score [39,40,86,175] (Table 9).
Analysis by immunohistochemistry failed to detect IL-6 in the cirrhotic liver, thus excluding a
possibly raised hepatic production as the cause for induced serum levels [39]. IL-6 is markedly lower
in the hepatic compared to the portal vein of healthy-liver controls and is also reduced in the patients
albeit to a lesser extent (Table 2). Therefore, impaired removal by the cirrhotic liver may constitute one
mechanism contributing to higher systemic levels [16]. Indeed, only 6.3% of portal vein IL-6 is cleared
by the cirrhotic liver, while about 40% is removed by the healthy liver [86]. Hepatic removal of IL-6
declines with increasing Child-Pugh score, and this may contribute to positive associations of systemic
IL-6 levels and liver dysfunction [39,40,86,175] (Table 9).
IL-6 is further increased in serum of patients with ascites [86,121]. It is about 12-fold higher in
ascites than in serum, demonstrating strongly induced production in the peritoneal cavity [121], which
may partly contribute to higher circulating levels in those patients.
Portal hypertension leads to ascites and is positively correlated with serum IL-6. Hepatic
IL-6 removal is not associated with the hepatic venous pressure gradient, and lowering of portal
hypertension by TIPS has no effect on systemic IL-6 levels [86,176]. Therefore, portal hypertension
does not affect IL-6 levels in patients with ascites.
A separate study has analyzed whether IL-6 is linked to hepatic encephalopathy. The authors
have identified positive correlations of serum IL-6 with plasma ammonia and severity of overt hepatic
encephalopathy [181].
Impaired uptake of IL-6 by the liver is linked to inappropriate IL-6 signaling and, thus, poor
acute phase response in these patients [170,176]. Low expression of the hepatic IL-6 receptor and high
circulating soluble gp130 further disturb IL-6 signaling [176].
Though IL-6 is supposed to contribute to hepatic insulin resistance, its levels are similar in cirrhotic
patients with normal and high HOMA-IR [174,182].
High IL-6 in patients with liver cirrhosis is partly due to impaired hepatic clearance. This
contributes to low hepatic IL-6 signaling and a poor acute phase response.
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Table 9. IL-6 levels in patients of 10 cohorts with liver cirrhosis. Cohort size, % males, age, body mass
index (BMI) and disease etiology are listed. Numbers are given as the mean ± standard deviation, or
the standard error of the mean (SEM), or as the median and range. ↑ indicates higher systemic levels
compared to the controls. The table also lists associations of serum IL-6 with the Child-Pugh or model
for end-stage liver disease (MELD) score. n.d., not described; HC, healthy-controls; CLD, non-cirrhotic
chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus.
Number of
Patients
(% Male)
Age (Years) BMI(kg/m2) Etiology Serum Levels
Positive
Associations in
Patients
Reference
41 (56) 55 (40–81) n.d. Mixed n.d. Child-Pugh (trend) [86]
43 (63) 56 (32–76) n.d. Alcohol ↑ HC Child-Pugh (trend) [177]
41 (63) 58 (29–74) 25.5 ± 0.9 HCV No change, HC No [177]
70 (60) 48.3 ± 11.1 n.d. HBV ↑ HC, ↑ CLD n.d. [153]
111 (60) 46 (18–70) n.d. Mixed ↑ HC, ↑ CLD Child-Pugh [40]
79 (62) 54.7 ± 14.7 ↑ HC n.d. [174]
72 (67) 56.6 (36–75) n.d. HCV ↑ HC Child-Pugh (trend) [39]
72 (71) 53 (46–60) Mixed No change, HC Child-Pugh [183]
45 (38) n.d. n.d. Alcohol ↑ (trend) HC Child-Pugh (trend) [175]
14 (78.6) 54 (44–59) n.d. Mostly HCV ↑ HC MELD [184]
3. Conclusions
Systemic levels of adiponectin, omentin, resistin, galectin-3 and IL-6 are higher in patients with
liver cirrhosis, while chemerin is reduced. Concentrations of these adipokines are partly correlated
with residual liver function. Whether there are any causal relationships between changed adipokine
levels and worse liver function cannot be evaluated in cross-sectional studies. Though adiponectin has
been described as a protective adipokine, current evidence does not support a beneficial function in
critically ill patients. Biologic activity of systemic adipokines not only depends on total concentrations,
but is also affected by receptor levels, the formation of multimers in the case of adiponectin and
proteolysis in the case of chemerin [2,87,185]. The pathophysiological relevance of changed systemic
adipokines in liver cirrhosis patients has not been clarified yet.
4. Perspectives
Though numerous studies have analyzed circulating adipokines in liver cirrhosis, their
pathophysiological role is still unclear. Adipokines are released from adipose tissues and contribute to
disease severity. Excess adipose tissue may accelerate disease progression, while its loss in advanced
disease is also harmful. Whether fat depot distribution has an effect herein has not been analyzed in
more detail yet. Data on circulating visfatin in liver cirrhosis are not concordant, and further studies
are needed to clarify whether its levels are altered in the disease. Further, most studies have compared
systemic adipokines in patients with liver cirrhosis and healthy controls. Here, appropriate patients
with non-cirrhotic liver have to be enrolled to confirm that changed adipokine levels are indeed related
to liver cirrhosis and not to the underlying disease. Experiments in preclinical models are needed to
resolve the function of altered adipokines in liver cirrhosis. Prospective studies in human cohorts may
be performed in the future to identify functional associations in the patients.
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